Dyne Therapeutics to Present at Morgan Stanley 22nd Annual Global Healthcare Conference
Dyne Therapeutics (Nasdaq: DYN), a clinical-stage muscle disease company, has announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Dyne Therapeutics (Nasdaq: DYN), a clinical-stage muscle disease company, has announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference. The event is scheduled for September 5, 2024, at 4:05 p.m. ET in New York.
Management will engage in a fireside chat during the conference. Investors and interested parties can access a live webcast of the presentation through Dyne's website in the Investors & Media section. The replay will remain available for 90 days after the event.
This participation highlights Dyne's commitment to advancing innovative therapeutics for individuals with genetically driven muscle diseases and provides an opportunity for the company to share insights with the healthcare investment community.
Details
News Market Reaction – DYN
The recorded move for DYN in the trading session of this news was +0.56%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WALTHAM, Mass., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to participate in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference being held in New York on Thursday, September 5, 2024 at 4:05 p.m. ET.
A live webcast will be available in the Investors & Media section of Dyne’s website at https://investors.dyne-tx.com/news-and-events/events-and-presentations and a replay will be accessible for 90 days following the presentation.
About Dyne Therapeutics
Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases. With its proprietary FORCE™ platform, Dyne is developing modern oligonucleotide therapeutics that are designed to overcome limitations in delivery to muscle tissue. Dyne has a broad pipeline for serious muscle diseases, including clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD) and a preclinical program for facioscapulohumeral muscular dystrophy (FSHD). For more information, please visit https://www.dyne-tx.com/, and follow us on X, LinkedIn and Facebook.
Contact:
Amy Reilly
areilly@dyne-tx.com
857-341-1203
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.